Author:
Ichikawa W,Uehara K,Minamimura K,Tanaka C,Takii Y,Miyauchi H,Sadahiro S,Fujita K,Moriwaki T,Nakamura M,Takahashi T,Tsuji A,Shinozaki K,Morita S,Ando Y,Okutani Y,Sugihara M,Sugiyama T,Ohashi Y,Sakata Y
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res 60: 6921–6926.
2. Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, Rogatko A, Wang H, Blanchard RL (2005) UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 11: 1226–1236.
3. Chen YJ, Hu F, Li CY, Fang JM, Chu L, Zhang X, Xu Q (2014) The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis. Biomarkers 19: 56–62.
4. Dias MM, McKinnon RA, Sorich MJ (2012) Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis. Pharmacogenomics 13: 889–899.
5. Dias MM, Pignon J-P, Karapetis CS, Boige V, Glimelius B, Kweekel DM, Lara PN, Laurent-Puig P, Martinez-Balibrea E, Páez D, Punt CJA, Redman MW, Toffoli G, Wadelius M, McKinnon RA, Sorich MJ (2014) The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis. Pharmacogenomics J 14: 424–431.
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献